1[1]Verghese A, Prabhu K, Diamond RD, et al. Synchronous bacterial and fungal septicemia: a marker for the critically ill surgical patient[J]. Amer Surg, 1988,54 :276-283 被引量：1
2[2]Burd RS, Raymond CS, Dunn DL. Endotoxin promotes synergistic lethality during concurrent Escherichia coli and Candida albicans infection[J]. J Surg Res, 1992,52 : 537-542 被引量：1
3[3]Carlson E. Enhancement by Candida albicans of Staphylococcus aureus, Serratia marcescens, and Streptococcus faecalis in the establishment of infection in mice[J]. Infect Immun, 1983,39: 193-197 被引量：1
4[4]Munster AM, Winchurch RA, Thupari JN, et al. Reversal of postburn immunosuppression with low-dose polymyxin B[J]. J Trauma, 1986, 26:995-998 被引量：1
5[5]Akagawa G, Abe S, Yamaguchi H. Mortality of Candida albicans-infected mice is facilitated by superinfection of Escherichia coli or administration of its lipopolysaccharide[J]. J Infect Dis,1995,171 : 1539-1544 被引量：1
6[6]Yin N, MarshallRL, MathesonS, etal. Synthesis of lipid A derivatives and their interactions with polymyxin B and polymyxin B nonapeptide. [J] . J Am Chem Soc,2003,125,2426-2435 被引量：1
7[7]Bone Re. Sepsis syndrome and the systemic inflammatory syndrome[J]. JAMA, 1995,273,155-156 被引量：1
8[8]Detmer K, Wang Z, Warejcka D, et al. Endotoxin stimulated cytokine production in rat vascular smooth muscle cells[J]. Am J Physiol Heart Circ Physiol, 2001,281 : H661-668 被引量：1
9Franz R,Kelly SL,Lamb DC,et al. Multiple Molecular mechanisms comtribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains[J]. Antimicrob Agents Chemother, 1998,42 : 3065-3072. 被引量：1
10White TC, Holleman S, Dy F, et al. Resistance mechanisms in clinical isolates of Candida albicans[J]. Antimicrob Agents Chemother, 202,46 : 1704-1713. 被引量：1
